Akorn takes on second FDA warning letter with companywide action plan

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Iido Frazao)
(Image: Getty/ Iido Frazao)

Related tags: Fda, Form 483, Akorn, Manufacturing, New jersey, illinois, Transparency, compliance

Akorn received a warning letter from US FDA after an inspection at its Somerset, New Jersey manufacturing facility in July and August of 2018.

This is the second warning letter the specialty drug manufacturer has received from the US Food and Drug Administration (FDA) regarding its facility.

The FDA sent the company a warning letter in January 2019 regarding its Decatur, Illinois facility not long after the agency issued a Form 483​ in November of that year regarding the inspection that took place at the Somerset facility between July 23 and August 30.

The Form 483 for the Somerset facility noted 11 observations​, including the finding that batches of Akorn’s ophthalmic solution, that had failed stability testing, entered the US market. Additional observations included issues with laboratory controls lacking appropriate test produces to assure drug products meet the appropriate standards.

In a statement addressing the warning letter, Akorn President and CEO Douglas Boothe said Akorn has launched a companywide action plan to improve its operations and, quality systems, and will also focus on transparency, he said.

Boothe added that the company will work to resolve all issues raised by the agency’s letter and expects to continue production at the Somerset facility.

Akorn’s shares have fallen 70.5% over the past 12 months.

Related news

Show more

Related products

show more

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Facilities: Lexington, KY USA

Facilities: Lexington, KY USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Lexington, KY USA is a fully integrated site which offers analytical, formulation development, and manufacturing...

Related suppliers

Follow us

Products

View more

Webinars